Two federal programs that have been driving innovation for 40 years by providing seed funding to entrepreneurs are in danger of running out of money - unless Congress acts by September 30, according to the USA’s Biotechnology Innovation Organization (BIO).
The Small Business Innovation Research and Small Business Technology Transfer (SBIR/STTR) programs typically give up to $250,000 for the first year of development of an idea and up to $750,000 more if the idea proves feasible.
The grants provide good value - generating “a 22:1 return for every federal dollar spent,” with “a commercialization rate of between 50-60% for SBIR/STTR investments,” according to the Arizona Bioindustry Association (AZ BIO). Many BIO members have used the grants to commercialize innovations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze